- After 15 years helping lead early cancer research at Genentech, Malek jumps ship to run Novartis' NIBR oncology unit
- Sanofi tries to quiet naysayers with follow-up data on MS drug at heart of $3.7B Principia buyout
- Rectify's work on ABCs lands $100M series A with Vertex founding scientist
- Sponsored: Purify DNA, RNA, proteins, and cells for many applications
- Omega, eyeing new uses for genome-tuning tech, taps Stanford to find ocular disease targets
- Sponsored: Partnership to unlock the full potential of data to advance the science and practice of healthcare: Q&A with Syntropy and the University of California, Irvine
- OnKure sets Diamond in C-suite ahead of Pfizer drug combo trial
- Olympus investigating 'potential cybersecurity incident' on American IT systems, its 2nd in a month
- Decentralized clinical trials skyrocketed during pandemic, but patient experience mixed bag: survey
- Olympian joins Eli Lilly to level the field for health inequity in breast cancer
- Novel protein degrader against 'undruggable' cancer target inhibits tumors in mice
- Headspace, Ginger finalize merger to form $3B mental health company
Featured Story | By Ben Adams The Novartis Institutes for BioMedical Research's oncology department has poached Genentech’s Shiva Malek, Ph.D., to help lead its cancer research. read more |
| |
|---|
|
Top Stories By Annalee Armstrong Sanofi’s $3.7 billion acquisition of Principia Biopharma has been taking barbs from all sides, so perhaps some long-term follow-up data on the multiple sclerosis candidate at the heart of the deal will quiet the criticism. read more By Kyle LaHucik Jonathan Moore was a founding scientist at Vertex, now he's leading the ABC charge at Rectify Pharmaceuticals as chief scientific officer. The biotech now has $100 million in its attempt to restore ABC transporters, a group of proteins that contain mutations that lead to loss of function in multiple organs. read more Sponsored by: Thermo Fisher Scientific Discover ways your Thermo Scientific™ KingFisher™ system can empower your research beyond SARS-CoV-2. read more By Nick Paul Taylor Omega Therapeutics is branching out. Having pulled off a $126 million IPO, the epigenomic specialist has teamed up with Stanford University School of Medicine to find eye disease targets to hit with its technology. read more Sponsored by: Syntropy Q&A with Syntropy and UCI on their collaboration to work across their enterprise and with external partners to advance health research and patient care. read more By Nick Paul Taylor OnKure Therapeutics has put another piece of its C-suite in place, hiring Jennifer Diamond as chief medical officer to support clinical development of its pipeline of cancer medicines. read more By Andrea Park The suspected incident occurred almost exactly one month after Olympus reported an attempted malware attack on its IT systems in Europe, the Middle East and Africa. read more By Kyle LaHucik About 87% of CRO and sponsors use decentralized/hybrid trials or plan to within 12 months compared to 28% before the pandemic, according to a new survey by Veeva. Yet, 56% of the clinical R&D leaders said the digital trials improved convenience or retention for patients. read more By Sharon Klahr Coey U.S. Olympian and American high jump record-holder Chaunté Lowe is putting the same amount of passion and grit into helping level the playing field for Black women with breast cancer as she does with her sport. read more By Angus Liu Riding a growing interest in protein degradation, researchers at the Indiana University School of Medicine identified a small-molecule degrader for a cancer-promoting target called SUMO1, which was previously considered "undruggable." The compound inhibited tumor growth in mouse models of human breast, colon and lung cancers being developed by startup HB Therapeutics. read more By Heather Landi Less than two months after the deal was announced, Headspace and Ginger have closed their merger, creating a $3 billion mental health company. Headspace Health aims to provide employees a full range of mental health services, from coaching, therapy and psychiatric care to meditation. read more Resources Sponsored By: Unlearn AI Read Unlearn’s whitepaper to learn about how novel trial designs with Digital Twins enable more efficient clinical trials, with higher power and smaller required sample sizes. Sponsored By: Trial Interactive Check out the eTMF Implementation Quick Guide to see a checklist TMF experts developed to help you reduce risks, maintain compliance, and establish effective processes in your eTMF. Sponsored By: Bioclinica This whitepaper addresses where AI can make the biggest impact in clinical trials. Sponsored by: Thermo Fisher Scientific Looking to accelerate your biotech company, but not sure where to start? Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: LabVantage Solutions Shift from data collection to data science. Add advanced analytics to your lab informatics platform to yield valuable, action-ready insights from LIMS and other data. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Thermo Fisher Scientific Integrate supply chain simulation into your early clinical trial planning to minimize risk in an uncertain supply chain environment, improve supply chain outcomes, and help streamline time-to-market for innovative therapies. Sponsored by: WCG Every biopharma sponsor faces the challenge of initiating, running and closing trials on time, but oncology studies pose several unique hurdles. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. | 
.png)
